Jay S. Duker, M.D. is the President & CEO and Board Director of EyePoint, a biopharmaceutical company that develops sustained-release medications to treat serious ocular disorders. Dr. Duker has devoted more than 30 years to the field of ophthalmology focused on improving eyesight and preventing blindness, holding roles in clinical research, business, and academic settings. Dr. Duker joined EyePoint in 2020. Prior to becoming President & CEO in July 2023, Dr. Duker served EyePoint as President and Chief Operating Officer, and as Chief Strategic Scientific Officer. He also served on EyePoint’s Board of Directors from 2016-2020 prior to his re-appointment to the Board of Directors in July 2023.
Between 2001 and 2021, Dr. Duker was the Director of the New England Eye Center (NEEC) and Professor and Chair of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine in Boston, Massachusetts. He has published over 345 journal articles, concentrating on retinal imaging, retinal vascular diseases, and drug delivery to the posterior segment. Dr. Duker remains in clinical practice, seeing patients with medical retinal disorders and intraocular tumors.
Dr. Duker is the founder of three successful start-up companies; SurgiSite Boston, the fifth busiest independent ophthalmology-only out-patient surgery center in the United States, the Boston Image Reading Center (BIRC), and Hemera Biosciences, the developer of HMR59, an AAV-based gene therapy for dry age-related macular degeneration that is now in a ph2 clinical trial after being acquired by Janssen in 2020. Dr. Duker was on the Board of Sesen Bio and served as its Chair. Dr. Duker received an A.B. from Harvard University and an M.D. from the Jefferson Medical College of Thomas Jefferson University.
What is Jay S. Duker's net worth?
The estimated net worth of Jay S. Duker is at least $1.35 million as of March 16th, 2026. Duker owns 100,665 shares of Eyepoint Pharmaceuticals stock worth more than $1,353,944 as of March 16th. This net worth estimate does not reflect any other investments that Duker may own. Additionally, Duker receives an annual salary of $848,500.00 as CEO at Eyepoint Pharmaceuticals. Learn More about Jay S. Duker's net worth.
What is Jay S. Duker's salary?
How do I contact Jay S. Duker?
Has Jay S. Duker been buying or selling shares of Eyepoint Pharmaceuticals?
During the past quarter, Jay S. Duker has bought $19,725.00 of Eyepoint Pharmaceuticals stock. Most recently, on Monday, March 16th, Jay S. Duker bought 1,500 shares of Eyepoint Pharmaceuticals stock. The stock was acquired at an average cost of $13.15 per share, with a total value of $19,725.00. Following the completion of the transaction, the chief executive officer now directly owns 100,665 shares of the company's stock, valued at $1,323,744.75. Learn More on Jay S. Duker's trading history.
Who are Eyepoint Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Eyepoint Pharmaceuticals?
During the last twelve months, Eyepoint Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,500 shares worth more than $19,725.00. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 42,544 shares worth more than $727,502.40. The most recent insider tranaction occured on March, 16th when CEO Jay S Duker bought 1,500 shares worth more than $19,725.00. Insiders at Eyepoint Pharmaceuticals own 4.5% of the company.
Learn More about insider trades at Eyepoint Pharmaceuticals. Information on this page was last updated on 3/16/2026.
